Skip to main content

Featured

Shopify Just Pushed the TSX to a Record — Should You Be Buying, or Is It Too Late?

  Published August 6, 2026 If you glanced at the markets on Wednesday and saw the TSX hit another record high, there's a good chance one company did most of the heavy lifting: Shopify. The S&P/TSX Composite closed up 344.83 points, or 1%, at 36,146.42 on August 5 — its second straight record close. Shopify shares jumped 16.5%, their biggest one-day move in a year, after the Ottawa-based e-commerce company beat earnings expectations and issued a stronger-than-expected outlook for the rest of the year. Gold miners added to the rally too, as bullion prices climbed. What It Means for You: If you own a Canadian equity index fund or ETF in your RRSP or TFSA, you almost certainly own a slice of this move already — whether you meant to or not. What actually happened Shopify reported second-quarter revenue of $3.58 billion (U.S.), up 34% from a year earlier and well ahead of the roughly $3.45 billion analysts expected. Adjusted earnings came in at $0.42 a share versus the $0.40 expecte...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment